137 related articles for article (PubMed ID: 30362515)
1. Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas.
Cui M; Hu Y; Bi Y; Wang W; Wang M; Zhang X; Zhang R; Wang P; Su Z; Gao X; Wang J; Li Q; Liao Q; Zhao Y
Int J Cancer; 2019 Feb; 144(3):525-532. PubMed ID: 30362515
[TBL] [Abstract][Full Text] [Related]
2. The genomic profile of parathyroid carcinoma based on whole-genome sequencing.
Hu Y; Zhang X; Wang O; Bi Y; Xing X; Cui M; Wang M; Tao W; Liao Q; Zhao Y
Int J Cancer; 2020 Nov; 147(9):2446-2457. PubMed ID: 32574388
[TBL] [Abstract][Full Text] [Related]
3. Genetic profiling as a clinical tool in advanced parathyroid carcinoma.
Kutahyalioglu M; Nguyen HT; Kwatampora L; Clarke C; Silva A; Ibrahim E; Waguespack SG; Cabanillas ME; Jimenez C; Hu MI; Sherman SI; Kopetz S; Broaddus R; Dadu R; Wanland K; Williams M; Zafereo M; Perrier N; Busaidy NL
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1977-1986. PubMed ID: 31309300
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
6. Complete genomic landscape of a recurring sporadic parathyroid carcinoma.
Kasaian K; Wiseman SM; Thiessen N; Mungall KL; Corbett RD; Qian JQ; Nip KM; He A; Tse K; Chuah E; Varhol RJ; Pandoh P; McDonald H; Zeng T; Tam A; Schein J; Birol I; Mungall AJ; Moore RA; Zhao Y; Hirst M; Marra MA; Walker BA; Jones SJ
J Pathol; 2013 Jul; 230(3):249-60. PubMed ID: 23616356
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
8. Previously unreported deletion of CDC73 involving exons 1-13 was detected in a patient with recurrent parathyroid carcinoma.
Mahajan G; Sacerdote A
BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567092
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion.
Yu W; McPherson JR; Stevenson M; van Eijk R; Heng HL; Newey P; Gan A; Ruano D; Huang D; Poon SL; Ong CK; van Wezel T; Cavaco B; Rozen SG; Tan P; Teh BT; Thakker RV; Morreau H
J Clin Endocrinol Metab; 2015 Feb; 100(2):E360-4. PubMed ID: 25387265
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.
Ross JS; Gay LM; Wang K; Vergilio JA; Suh J; Ramkissoon S; Somerset H; Johnson JM; Russell J; Ali S; Schrock AB; Fabrizio D; Frampton G; Miller V; Stephens PJ; Elvin JA; Bowles DW
Ann Oncol; 2017 Oct; 28(10):2539-2546. PubMed ID: 28961851
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid carcinoma: molecular therapeutic targets.
Marini F; Giusti F; Palmini G; Aurilia C; Donati S; Brandi ML
Endocrine; 2023 Sep; 81(3):409-418. PubMed ID: 37160841
[TBL] [Abstract][Full Text] [Related]
16. [CDC73 gene mutation and parafibromin expression status of parathyroid carcinoma in Chinese].
Kong J; Wang O; Nie M; Shi J; Jiang Y; Li M; Xia WB; Meng XW; Xing XP
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(42):3364-8. PubMed ID: 24418033
[TBL] [Abstract][Full Text] [Related]
17. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.
Jacob JM; Ferry EK; Gay LM; Elvin JA; Vergilio JA; Ramkissoon S; Severson E; Necchi A; Killian JK; Ali SM; Schrock AB; Liu NW; Chung J; Miller VA; Stephens PJ; Welsh A; Corona RJ; Ross JS; Bratslavsky G
J Urol; 2019 Mar; 201(3):541-548. PubMed ID: 30291913
[TBL] [Abstract][Full Text] [Related]
18. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling reveals mutational landscape in parathyroid carcinomas.
Pandya C; Uzilov AV; Bellizzi J; Lau CY; Moe AS; Strahl M; Hamou W; Newman LC; Fink MY; Antipin Y; Yu W; Stevenson M; Cavaco BM; Teh BT; Thakker RV; Morreau H; Schadt EE; Sebra R; Li SD; Arnold A; Chen R
JCI Insight; 2017 Mar; 2(6):e92061. PubMed ID: 28352668
[TBL] [Abstract][Full Text] [Related]
20. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
